

Poster presentation

Open Access

## Efficacy of linezolid (LZD), vancomycin (VAN) and its combinations with rifampin (RIF) in the treatment of experimental meningitis due to methicillin-resistant *Staphylococcus aureus*

Carmen Garrigósc\*, M Eugenia Pachón-Ibáñez, Carmen Cabellos, Óscar Murillo, Enriqueta Force, Ferrán Taberner, Marta Cardiel and Francesc Gudiol

Address: IDIBELL, Hospital Universitari de Bellvitge, L' Hospitalet de Llobregat, Barcelona, 08907, Spain

Email: Carmen Garrigósc\* - garrigos.vacas@hotmail.com

\* Corresponding author

from Infectious diseases of the nervous system: pathogenesis and worldwide impact  
Paris, France. 10–13 September 2008

Published: 23 September 2008

BMC Proceedings 2008, 2(Suppl 1):P21

This abstract is available from: <http://www.biomedcentral.com/1753-6561/2/S1/P21>

© 2008 Garrigósc et al; licensee BioMed Central Ltd.

### Objective

To study the *in vitro* and *in vivo* activity of LZD, VAN and its combinations with RIF in a rabbit meningitis model, caused by two strains of *S. aureus* with different susceptibilities to glycopeptides.

### Methods

#### *In vitro*

MICs (mg/L): Strain A (LZD = 2, VAN = 1, RIF = 0.018) and B (LZD = 4, VAN = 8, RIF = 512). The bactericidal activity and synergy (time-kill curves) were studied over 24 h. Drugs were tested for a range of concentrations according to their MICs and achievable human serum levels (1/4x-4xMIC) against both strains.

#### *In vivo*

New Zealand rabbits (2.5–3 kg) were used, with an inoculum of 8.5–9 Log cfu/mL. PK/PD parameters (blood and CSF) were determined (C<sub>max</sub> [mg/L]; AUC [mg.h/L]; t<sub>1/2</sub> [h]; t > MIC [h]; AUC/MIC) after a single dose of each antimicrobial on infected rabbits. In the therapy experiments, animals (n = 6 per schedule) were grouped in untreated (CON), or treated with LZD (20 mg/kg), VAN (25 mg/kg every 4 hours, 4 doses), RIF (15 mg/kg) every 24 hours (1 dose), LZD+RIF or VAN+RIF. CSF variables analyzed at 0, 4, 6 and 24 h of treatment were: bacterial

concentration (Log<sub>10</sub> cfu/mL), WBC (cells/mL), lactate (mmol/L) and protein concentration (g/L). Statistical Analysis: Wilcoxon and Anova test were used.

### Results

#### *In vitro*

The following schedules were bactericidal: Strain A: LZD (4xMIC) and the following combinations RIF (2xMIC)+LZD(4xMIC), RIF (1xMIC)+LZD (1/2xMIC), RIF (1/2xMIC)+LZD (1xMIC); and strain B: VAN (4xMIC, 2xMIC) and the combinations of both drugs with RIF.

#### *In vivo*

PK/PD C<sub>max</sub> (µg/mL): Blood: LZD 20.84, VAN 59.59, RIF 52.38, CSF: LZD 4.64, VAN 4.12; RIF 1.22. Percentage of penetration: LZD 19%; VAN 15%; RIF 3.8%.

Bacterial concentration (0, 4, 6, 24 h): Strain A: CON (4.94, 4.48, 4.76, 4.65), LZD (4.96, 4.71, 4.81, 4.27), VAN (5.25, 4.62, 4.30, 4.95), RIF (5.32, 5.65, 5.19, 4.80), LDZ+RIF (4.85, 4.90, 4.82, 4.17) and VAN+RIF (5.34, 5.30, 5.36, 4.61); Strain B: CON (5.19, 4.67, 4.81, 4.37), LZD (4.85, 4.37, 4.18, 3.67), VAN (5.00, 5.63, 4.79, 4.79) and LDZ+RIF (5.02, 4.90, 4.53, 4.21). For Strain B, LZD and LZD+RIF significantly reduced bacterial concentra-

tion (24 h vs. 0 h,  $p < 0.05$ ). LZD reduced the CSF lactate and proteins levels (24 h vs. 0 h,  $p < 0.05$ ).

### Conclusion

In this model of experimental meningitis caused by a GISA strain, linezolid and linezolid plus rifampin were effective reducing the CSF bacterial concentration and inflammatory parameters.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

